Akero Therapeutics Stock Price on September 4, 2024
| AKRO Stock | USD 32.73 1.53 4.90% |
Below is the normalized historical share price chart for Akero Therapeutics extending back to June 20, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Akero Therapeutics stands at 32.73, as last reported on the 22nd of November, with the highest price reaching 32.95 and the lowest price hitting 31.05 during the day.
If you're considering investing in Akero Stock, it is important to understand the factors that can impact its price. Akero Therapeutics appears to be very steady, given 3 months investment horizon. Akero Therapeutics secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11% return per unit of standard deviation over the last 3 months. We have found twenty-eight technical indicators for Akero Therapeutics, which you can use to evaluate the volatility of the firm. Please makes use of Akero Therapeutics' mean deviation of 2.34, and Risk Adjusted Performance of 0.0826 to double-check if our risk estimates are consistent with your expectations.
At this time, Akero Therapeutics' Total Stockholder Equity is very stable compared to the past year. As of the 22nd of November 2024, Liabilities And Stockholders Equity is likely to grow to about 609.3 M, while Common Stock Total Equity is likely to drop 2,933. . At this time, Akero Therapeutics' Price Book Value Ratio is very stable compared to the past year. As of the 22nd of November 2024, Price To Book Ratio is likely to grow to 2.41, while Price Earnings Ratio is likely to drop (8.49). Akero Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 20th of June 2019 | 200 Day MA 25.2757 | 50 Day MA 29.7333 | Beta (0.26) |
Akero |
Sharpe Ratio = 0.1058
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AKRO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.11 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.33 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Akero Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Akero Therapeutics by adding it to a well-diversified portfolio.
Price Book 2.8961 | Book Value 10.606 | Enterprise Value 1.5 B | Enterprise Value Ebitda (6.77) | Shares Float 55.4 M |
Related Headline
SAB Biotherapeutics Headline on 4th of September 2024
SAB BIO to Present at the European Association for the Study... by finance.yahoo.com
MIAMI, Sept. 04, 2024 -- SAB BIO , a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes , today announced that it will present at the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024 in Madrid. SABs Executive Vice President and Chief Medical Officer Alexandra
Akero Therapeutics Valuation on September 4, 2024
It is possible to determine the worth of Akero Therapeutics on a given historical date. On September 4, 2024 Akero was worth 25.71 at the beginning of the trading date compared to the closed value of 26.3. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Akero Therapeutics stock. Still, in general, we apply an absolute valuation method to find Akero Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Akero Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Akero Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 27.16 | 28.30 | 25.96 | 25.99 | 429,103 | |
09/04/2024 | 25.71 | 26.41 | 25.31 | 26.30 | 197,361 |
| 26.40 | 26.43 | 25.73 | 26.35 | 444,088 |
| Backtest Akero Therapeutics | | | Akero Therapeutics History | | | Akero Therapeutics Valuation | Previous | Next |
Akero Therapeutics Trading Date Momentum on September 4, 2024
| On September 05 2024 Akero Therapeutics was traded for 26.35 at the closing time. The top price for the day was 26.43 and the lowest listed price was 25.73 . The trading volume for the day was 444.1 K. The trading history from September 5, 2024 was a factor to the next trading day price boost. The overall trading delta against the next closing price was 0.19% . The overall trading delta against the current closing price is 4.18% . |
Akero Therapeutics Fundamentals Correlations and Trends
By evaluating Akero Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Akero Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Akero financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Akero Therapeutics Stock history
Akero Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Akero is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Akero Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Akero Therapeutics stock prices may prove useful in developing a viable investing in Akero Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 52.6 M | 34.6 M | |
| Net Loss | -100.8 M | -105.9 M |
Akero Therapeutics Quarterly Net Working Capital |
|
Akero Therapeutics Stock Technical Analysis
Akero Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Akero Therapeutics Period Price Range
Low | November 22, 2024
| High |
0.00 | 0.00 |
Akero Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Akero Therapeutics November 22, 2024 Market Strength
Market strength indicators help investors to evaluate how Akero Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Akero Therapeutics shares will generate the highest return on investment. By undertsting and applying Akero Therapeutics stock market strength indicators, traders can identify Akero Therapeutics entry and exit signals to maximize returns
Akero Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Akero Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Akero Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Akero to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0826 | |||
| Jensen Alpha | 0.0923 | |||
| Total Risk Alpha | (0.11) | |||
| Sortino Ratio | 0.0649 | |||
| Treynor Ratio | 0.1454 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Akero Stock, please use our How to Invest in Akero Therapeutics guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akero Therapeutics. If investors know Akero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.78) | Return On Assets (0.23) | Return On Equity (0.36) |
The market value of Akero Therapeutics is measured differently than its book value, which is the value of Akero that is recorded on the company's balance sheet. Investors also form their own opinion of Akero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Akero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akero Therapeutics' market value can be influenced by many factors that don't directly affect Akero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.